Jump to ContentJump to Main Navigation

Online

249,00 € / $374.00*

* Prices subject to change. Shipping costs will be added if applicable.
Publication Date:
June 2005
ISSN:
1437-4331
DOI:
10.1515/CCLM.2001.155

See all formats and pricing

Online
Individual Subscription Online only
Euro [D] 249.00
RRP for USA, Canada, Mexico
US$ 374.00 *
Print
Individual Subscription Online only
Euro [D] 1577.00
RRP for USA, Canada, Mexico
US$ 2365.00 *
Print + Online
Individual Subscription Online only
Euro [D] 1893.00
RRP for USA, Canada, Mexico
US$ 2838.00 *
*Prices subject to change. Shipping costs will be added if applicable.

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the International Federation of Clinical Chemistry and Laboratory Medicine and the European Federation of Clinical Chemistry and Laboratory Medicine

Editor-in-Chief: Plebani, Mario

Editorial Board Member: Lippi, Giuseppe / Gillery, Philippe / Kazmierczak, Steven / Lackner, Karl J. / Melichar, Bohuslav / Siest, Gérard / Whitfield, John B. / Abi Fadel, Marianne / Alvarez Menendez, Francisco V. / Azzazy, Hassan M.E. / Diamandis, Eleftherios P. / Eckardstein, Arnold / Favaloro, Emmanuel J. / Griesmacher, Andrea / Herrmann, Wolfgang / Hoffmann, Johannes J.M.L. / Hooijkaas, Herbert / Ichihara, Kiyoshi / Kaabachi, Naziha / Kim, Jeong-Ho / Korte, Wolfgang / Kroupis, Christos / Lai, Leslie Charles / Lam, Wai Kei Christopher / Marc, Janja / Miyoshi, Eiji / Özben, Tomris / Palicka, Vladimir / Panteghini, Mauro / Queralto, Jose M. / Scartezini, Marileia / Simundic, Ana-Maria / Tsongalis, Gregory J. / Wallemacq, Pierre E. / Yan, Shengkai / Young, Ian S. / Chiu, Rossa Wai Kwun / Ghosh, Debabrata / Kappelmayer, Janos / Lehmann, Sylvain / Sypniewska, Grazyna

12 Issues per year

Increased IMPACT FACTOR 2011: 2.150
Rank 10 out of 32 in category Medical Laboratory Technology in the 2011 Thomson Reuters Journal Citation Report/Science Edition

VolumeIssuePage

Issues

Serum 90K/MAC-2BP Glycoprotein in Patients with Liver Cirrhosis and Hepatocellular Carcinoma: a Comparison with α-Fetoprotein

Palma Aurelia Iacovazzi / Adriana Trisolini / Domenico Barletta / Silvana Elba / Onofrio Giuseppe Manghisi / Mario Correale

Citation Information: Clinical Chemistry and Laboratory Medicine. Volume 39, Issue 10, Pages 961–965, ISSN (Print) 1434-6621, DOI: 10.1515/CCLM.2001.155, June 2005

Publication History:
Published Online:
2005-06-01

Abstract

Glycoprotein 90K/MAC-2BP is a member of the scavenger receptor cystein-rich protein superfamily, which is thought to be involved in immune surveillance, defending the body against pathogens and cancer.

90K serum levels are elevated in patients with cancer of various origins and in viral infections, such as human immunodeficiency virus and hepatitis C virus (HCV). Because in patients with HCV-related cirrhosis the incidence of hepatocellular carcinoma (HCC) is high, in the present paper we examined, by means of an enzyme-linked immunosorbent assay, the 90K serum levels in 103 patients with liver cirrhosis, and in 69 with HCC, and compared them to α-fetoprotein, the reference tumor marker for this neoplasm.

Serum levels of 90K (cut-off 14 μg/ml) were elevated both in cirrhosis (39%) and HCC (46%) compared to controls (14.1 μg/ml vs. 10.6 μg/ml in cirrhosis, and 14.8 μg/ml vs. 9.1 μg/ml in HCC, p≤0.001). There was a significant association with the presence of anti-HCV antibodies. 90K was found to be a non-specific tumor marker which is complementary to α-fetoprotein on the basis of its probable different biological significance. In fact, 74% of HCC patients had at least one positive marker. Combined use of 90K and α-fetoprotein could improve the sensitivity of a single test in the diagnosis of HCC.

Comments (0)

Please log in or register to comment.